Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA.

Autor:	Ponraj, Royston, Bryant, Adam, Dunlop, Lindsay, Range, Heather, Cobrador, Cherry, Ling, Silvia, Hsu, Danny
Předmět:	PAROXYSMAL hemoglobinuria KIDNEY diseases THROMBOTIC thrombocytopenic purpura
Zdroj:	Blood Cancer Journal; 7/26/2023, Vol. 13 Issue 1, p1-4, 4p
Abstrakt:	Our study highlights the importance of monitoring patients receiving carfilzomib for haemolysis and end organ dysfunction, particularly in older patients and during concurrent infection. In carfilzomib-treated patients, we observed episodes of haemolysis associated with peripheral schistocytes in patients without overt TMA clinical features. Table 1 Patient baseline characteristics and survival - affected (patients who developed MAHA) vs unaffected (patients without MAHA). Second, both patients that developed severe TMA had evidence of a prior low-grade MAHA episode, and therefore this may be an indicator of increased risk in these patients. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink